Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Epistemonikos ID: e54def457f762c2b78a1bf7d9a88754944cf9007
First added on: Jan 21, 2022